Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Selank is a peptide developed in Russia as an anxiolytic and nootropic; in animal models it reduces anxiety-like behavior and modulates immune parameters under stress39, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While Selank works as a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, that combines a tuftsin fragment with a Pro-Gly-Pro motif and is reported to modulate GABAergic neurotransmission and cytokine balance while being resistant to proteolytic degradation39, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
Selank
Not assigned in the current dataset.
Semaglutide
GCG
Selank and Semaglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Selank is more often discussed in the realm of Neurology and brain health and Immunology and inflammation, whereas Semaglutide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. They also influence different molecular systems, with Selank tracking more closely to GPCR receptor while Semaglutide centers more on GLP-1 receptor. Both are synthetic in origin and their development context also differs, with Selank approved for Research use only while Semaglutide is approved. Selank takes the form of a linear peptide, whereas Semaglutide is closer to a peptide conjugate, Semaglutide incorporates lipidation features that are not part of Selank; while their sequence patterns also diverge, with Selank showing proline-rich features and Semaglutide showing alpha-helical domain features.